A year in Oncology

A Review of 2020 Drug Approvals & Key Milestones

Despite a global pandemic, 2020 saw a notable number of approvals of new anti-cancer therapies in the US, Europe and Japan – including the continued roll-out of immuno-oncology (I-O) therapies.

The US saw a similar number of new oncology drug/indication approvals in 2020 as in 2019. An even higher number were seen in Japan, largely due to approvals ahead of all other global regions (as per the Sakigake Designation Scheme) and the rollout of drugs already sanctioned by the FDA. In Europe, however, there were around a quarter fewer approvals in 2020 than in the prior year.

To view the approvals and the key milestones (in our view) in an easy-to-digest snapshot, please see Ipsos’ infographic, ‘A Year in Oncology: A Review of 2020 Drug Approvals in US, Europe & Japan’.

 

Related news

  • [Webinar] KEYS: Global Trends - The Uneasy Decade
    Global Trends Events replay

    [Webinar] KEYS: Global Trends - The Uneasy Decade

    At the next episode of our KEYS webinar, the Ipsos Global Trends team will be launching the findings of our latest report. This 9th edition explores how the trends that will shape the future are evolving, as the uneasy decade continues.
  • [Webinar] KEYS: Uncharted Territory
    Economy Events replay

    [Webinar] KEYS: Uncharted Territory

    The next episode of our KEYS webinar series is dedicated to what we’ve learned so far during 2025. Are we adapting fast enough? And are there areas where we need to change course?
  • [Webinar] KEYS: Tech-celeration
    Technology Events replay

    [Webinar] KEYS: Tech-celeration

    At our next KEYS webinar, we’ll be taking a moment to assess the role technology plays in today’s environment. What’s changing. And what’s staying the same?